A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Blood

Volumn 114, Issue 6, 2009, Pages 1166-1173

  Harousseau, Jean Luc ^a   Martinelli, Giovanni ^b   Jedrzejczak, Wieslaw W ^c   Brandwein, Joseph M ^d   Bordessoule, Dominique ^e   Masszi, Tamas ^f   Ossenkoppele, Gert J ^g   Alexeeva, Julia A ^h   Beutel, Gernot ⁱ   Maertens, Johan ^j   Vidriales, Maria Belen ^k   Dombret, Hervé ^l   Thomas, Xavier ^m   Burnett, Alan K ⁿ   Robak, Tadeusz ^o   Khuageva, Nuriet K ^p   Golenkov, Anatoly K ^q   Tothova, Elena ^r   Mollgard, Lars ^s   Park, Youn C ^t   Bessems, Annick ^t   De Porre, Peter ^t   Howes, Angela J ^t   more..

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f NATIONAL MEDICAL CENTER   (Hungary)

^g VU UNIVERSITY AMSTERDAM   (Netherlands)

^h City Center of Coloproctology   (Russian Federation)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l SAINT LOUIS HOSPITAL   (France)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^o MEDICAL UNIVERSITY OF LODZ   (Poland)

^p SP Botkin Municipal Clinical Hospital   (Russian Federation)

^q M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^r P J AFÁRIK UNIVERSITY   (Slovakia)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; TIPIFARNIB; ANTINEOPLASTIC AGENT; QUINOLONE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC CARE; HEART FAILURE; HUMAN; HYPOKALEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MORTALITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; SURVIVAL RATE; TIME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, ACUTE; MALE; NEUTROPENIA; QUINOLONES; SURVIVAL RATE; TIME FACTORS;

EID: 69849092737     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-198093     Document Type: Article

References (27)

1. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908-1915. (Pubitemid 46854425)
2. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18[Suppl 1]:i3-i8.
3. Jackson GH, Taylor PR. Acute myeloid leukaemia: optimising treatment in elderly patients. Drugs Aging. 2002;19:571-581.
4. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
6. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670-1673. (Pubitemid 30661044)
7. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576. (Pubitemid 29517929)
8. Schaich M. Elderly acute myeloid leukemia: patients are not all the same. Haematologica. 2004;89:261-263. (Pubitemid 38788405)
9. Fey MF, Greil R, Jost LM. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Ann Oncol. 2005;16[Suppl 1]:i48-i49. (Pubitemid 40872986)
10. Bolam S, Hamblin T. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia. Drugs Aging. 1999;15:451-460. (Pubitemid 30025748)
11. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin. 2002;52:363-371. (Pubitemid 35446607)
12. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22:943-955. (Pubitemid 41746575)
13. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597-1603. (Pubitemid 34773427)
14. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
15. Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age > or = 75 years. Cancer. 2004;101:325-331.
16. Kurzrock R, Kantarjian HM, Blascovich MA, et al. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008;14:509-514. (Pubitemid 351226120)
17. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007;109:4158-4163. (Pubitemid 46743377)
18. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
19. Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007;109:1387-1394. (Pubitemid 46242109)
20. Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008;111:2589-2596.
21. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89:3323-3329. (Pubitemid 27229818)
22. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/Pglycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086-1099.
23. Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am. 2000;14:251-267. (Pubitemid 30078441)
24. Litzow MR. The therapy of relapsed acute leukaemia in adults. Blood Rev. 2004;18:39-63.
25. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
26. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098. (Pubitemid 43297348)
27. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124. (Pubitemid 46435390)